Compare NICE Ltd (NICE) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NICE Ltd vs Zoetis Inc — how do they compare? NICE Ltd trades at $98.16 (market cap $6.02B), while Zoetis Inc trades at $73.04 (market cap $31.14B). The key difference: Zoetis Inc is far larger — about 5.2× NICE Ltd's market cap, and Zoetis Inc pays a 2.81% dividend while NICE Ltd pays none. Which is the better fit depends on your goals.
| NICE | ZTS | |
|---|---|---|
Market Cap | $6.02B | $31.14B |
Sector | Technology | Health |
52-Week High | $153.44 | $156.76 |
52-Week Low | $83.15 | $71.91 |
Enterprise Value | $5.75B | $38.70B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NICE stock trades at $98.36, down 4.1% over 24 hours, with a bullish technical signal from moving averages and a consensus analyst price target of $115. The company reported Q2 2026 earnings that beat expectations, with revenue growth of 7.6% year-over-year, and maintains strong profitability with a net income margin of 13.86%. Recent news highlights partnerships with Currys and RingCentral to enhance AI-powered customer engagement.
The outlook for NICE is positive, supported by consistent earnings beats, solid valuation metrics, and expanding AI integrations. Key risks include competitive pressures in the CX software space and potential volatility from macroeconomic factors. With no sell ratings from analysts and institutional interest, the stock presents a growth opportunity amid manageable risks.
Zoetis (ZTS) trades at $72.42, down 3.27% amid bearish technical signals and recent earnings pressure. The stock shows strong fundamentals with 27.69% net margins and 64.91% ROE, but faces headwinds from softening pet healthcare demand. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a lowered 2026 outlook. Analyst consensus remains positive with a $94.90 price target despite near-term challenges.
The outlook remains cautiously optimistic given ZTS's dominant market position and profitability, though near-term performance depends on reversing companion animal segment weakness. Investment opportunity exists at current discounted valuation (P/E 12.29), balanced against competitive pressures and class action litigation risks. Upside potential aligns with analyst targets if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
